Caplacizumab-yhdp (Cablivi)

Cablivi (caplacizumab‑yhdp) is covered only for adults (≥18) with acquired TTP when used in combination with plasma exchange and immunosuppressive therapy, initiated in the inpatient setting and prescribed by or in consultation with a hematologist; outpatient initiation and use in patients <18 are excluded. Coverage requires documentation of diagnosis and current immunosuppressive therapy, inpatient initiation with PEX and adherence to dosing/timing, ≤60 doses after the last PEX, no more than two aTTP recurrences while on Cablivi if previously treated, and authorization is limited to 2 months.

"Cablivi is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy."

Sign up to see full coverage criteria, indications, and limitations.